Publications de l'IFM

Publié le 21 janvier 2020

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
Erratum in: Lancet. 2019 Dec 7;394(10214):2072

Publié le 21 janvier 2020

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.

Clin Cancer Res. 2018 Nov 1;24(21):5219-5224. doi: 10.1158/1078-0432.CCR-18-0741. Epub 2018 Aug 1.

Publié le 21 janvier 2020

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Leukemia. 2018 Dec;32(12):2604-2616. doi: 10.1038/s41375-018-0037-9. Epub 2018 May 22.

Publié le 21 janvier 2020

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.

BMC Cancer. 2019 Aug 29;19(1):855. doi: 10.1186/s12885-019-6080-8

Publié le 21 janvier 2020

Multiple myeloma clonal evolution in homogeneously treated patients.

Leukemia. 2018 Dec;32(12):2636-2647. doi: 10.1038/s41375-018-0153-6. Epub 2018 Jun 12.

Publié le 21 janvier 2020

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19

Publié le 21 janvier 2020

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Blood. 2018 Dec 27;132(26):2778-2780. doi: 10.1182/blood-2018-09-876433. Epub 2018 Nov 14. No abstract available.

Publié le 21 janvier 2020

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Haematologica. 2019 Dec 19. pii: haematol.2019.236588. doi: 10.3324/haematol.2019.236588. [Epub ahead of print] No abstract available.

Publié le 21 janvier 2020

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

Publié le 21 janvier 2020

Response to pneumococcal vaccination in multiple myeloma.

Cancer Med. 2019 Jul;8(8):3822-3830. doi: 10.1002/cam4.2253. Epub 2019 May 30

Publié le 21 janvier 2020

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood. 2018 Dec 13;132(24):2555-2563. doi: 10.1182/blood-2018-07-863829. Epub 2018 Oct 3.

Publié le 21 janvier 2020

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.

Publié le 21 janvier 2020

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Br J Haematol. 2019 Nov;187(3):319-327. doi: 10.1111/bjh.16059. Epub 2019 Jun 19

Publié le 21 janvier 2020

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15

Publié le 21 janvier 2020

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3

Publié le 21 janvier 2020

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3.

Publié le 21 janvier 2020

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.
Sep 20. pii: haematol.2018.194282. doi: 10.3324/haematol.2018.194282. [Epub ahead of print]

Publié le 21 janvier 2020

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Leukemia. 2019 Sep;33(9):2324-2330. doi: 10.1038/s41375-019-0452-6. Epub 2019 Apr 9. No abstract available

Publié le 21 janvier 2020

Multiple myeloma immunophenotyping: method validation.

Ann Biol Clin (Paris). 2019 Apr 1;77(2):197-217. doi: 10.1684/abc.2019.1426.

Publié le 21 janvier 2020

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:675-680. doi: 10.1200/EDBK_200879. Review.

Publié le 21 janvier 2020

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.

Am J Hematol. 2019 Jun;94(6):635-640. doi: 10.1002/ajh.25459. Epub 2019 Apr 1

Publié le 21 janvier 2020

Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.

Clin Chem Lab Med. 2019 Aug 27;57(9):1397-1405. doi: 10.1515/cclm-2018-1369

Publié le 21 janvier 2020

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

Publié le 21 janvier 2020

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e228-e237. doi: 10.1016/j.clml.2019.01.007. Epub 2019 Jan 29.

Publié le 21 janvier 2020

Risk-Based Therapeutic Strategies.

Cancer J. 2019 Jan/Feb;25(1):54-58. doi: 10.1097/PPO.0000000000000352

Publié le 21 janvier 2020

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.

Leukemia. 2018 Jun;32(6):1267-1276. doi: 10.1038/s41375-018-0098-9. Epub 2018 Mar 28. Review.

Publié le 21 janvier 2020

Evaluation of infectious prevention practices in myeloma

Med Mal Infect. 2019 Feb;49(1):76-78. doi: 10.1016/j.medmal.2018.09.001. Epub 2018 Oct 5. French. No abstract available.

Publié le 21 janvier 2020

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

Publié le 21 janvier 2020

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
Erratum in: Lancet. 2019 Jun 14;:

Publié le 21 janvier 2020

Targeting Bcl-2 for the treatment of multiple myeloma.

Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3. Review.

Publié le 21 janvier 2020

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249

Publié le 21 janvier 2020

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

Publié le 21 janvier 2020

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.

Blood Cancer J. 2019 Mar 20;9(4):38. doi: 10.1038/s41408-019-0200-1

Publié le 21 janvier 2020

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.

Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197. No abstract available.

Publié le 21 janvier 2020

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.